KASINGER JAMES R. 4

4 · CRISPR Therapeutics AG · Filed Mar 24, 2026

AI-generated summary of this filing

Updated Mar 24, 2026

CRISPR (CRSP) GC James Kasinger Sells Shares, Receives Awards

What Happened

James R. Kasinger, General Counsel and Secretary of CRISPR Therapeutics (CRSP), had multiple equity-related transactions around March 20–23, 2026. He sold 3,182 common shares in an open‑market sale on 2026-03-23 at $46.78/share for total proceeds of $148,854. On 2026-03-20 he received new awards (an option covering 38,499 shares and an RSU award for 25,000 shares) and had 6,250 units convert/vest (derivative conversion tied to a prior RSU grant).
The sale reported was a sell-to-cover/tax‑related disposition associated with vesting shares (not a discretionary large sell). Some acquired shares remain subject to a lock‑up with underwriters.

Key Details

Transactions/dates:
- 2026-03-20: Conversion/exercise of derivative for 6,250 shares (derivative vest/convert).
- 2026-03-20: Grant/award of 38,499 shares (option) and 25,000 RSUs (new grant).
- 2026-03-23: Open‑market sale of 3,182 shares at $46.78 for $148,854 (disposed).
Shares owned after transaction: Not specified in the provided filing excerpt.
Notable footnotes:
- F1: Some shares remain subject to a lock‑up with underwriters of the issuer’s 2031 convertible note offering.
- F2: Each RSU is a contingent right to one common share.
- F3: The reported sale amount represents shares sold to satisfy tax withholding for vested RSUs per the company’s RSU Settlement Policy (a mandated sell‑to‑cover, not a discretionary trade).
- F4/F5/F6: Vesting schedules—the 38,499‑share option vests monthly over 48 months starting 4/20/2026; the 25,000 RSU grant vests in quarterly annual installments from 3/20/2027–3/20/2030; a 25,000 RSU grant from 2024 had one quarter (6,250 shares) vesting on 3/20/2026.
Filing timeliness: The Form 4 was filed 2026-03-24 for transactions dated 2026-03-20 and 2026-03-23; this filing date is within the typical two business‑day reporting window and appears timely.

Context

Derivative/RSU explanation: The 6,250‑share “M” entries reflect vested RSUs converting into common shares. The sale reported (3,182 shares) was a sell‑to‑cover to satisfy tax withholding obligations on vesting—common practice and not necessarily a signal of discretionary insider selling.
Awards vs. sales: The filing shows both newly granted compensation (options and RSUs) and a routine tax‑related sale. Purchases (which can signal direct bullish insider conviction) are not present here; the sale was mandated by company policy.

Form 4

Period: 2026-03-20

General Counsel and Secretary

Transactions

Exercise/Conversion
Common Shares
[F1][F2]
2026-03-20+6,250→ 97,490 total
Sale
Common Shares
[F3]
2026-03-23$46.78/sh−3,182$148,854→ 94,308 total
Award
Stock Option (Right to Buy)
[F1][F4]
2026-03-20+38,499→ 38,499 total
Exercise: $46.24Exp: 2036-03-20→ Common Shares (38,499 underlying)
Award
Restricted Stock Units
[F2][F1][F5]
2026-03-20+25,000→ 25,000 total
→ Common Shares (25,000 underlying)
Exercise/Conversion
Restricted Stock Units
[F2][F1][F6]
2026-03-20−6,250→ 12,000 total
→ Common Shares (6,250 underlying)

Footnotes (6)

[F1]These shares remain subject to a lock-up agreement with the underwriters of the Issuer's offering of convertible senior notes due 2031.
[F2]Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
[F3]Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.
[F4]This option was granted on March 20, 2026 with respect to 38,499 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 20, 2026.
[F5]This restricted stock unit award was granted on March 20, 2026 with respect to 25,000 Common Shares, with (i) one quarter of the shares vesting on March 20, 2027 , (ii) one quarter of the shares vesting on March 20, 2028, (iii) one quarter of the shares vesting on March 20, 2029, and (iv) one quarter of the shares vesting on March 20, 2030.
[F6]This restricted stock unit award was granted on March 20, 2024 with respect to 25,000 Common Shares, with (i) one quarter of the shares vesting on March 20, 2025, (ii) one quarter of the shares vesting on March 20, 2026, (iii) one quarter of the shares vesting on March 20, 2027, and (iv) one quarter of the shares vesting on March 20, 2028.

Signature

Elizabeth Ryland Waldinger, attorney-in-fact|2026-03-24

1 file